Skip to main content
Equibles

Jim DeTore

CFO

CG Oncology, Inc. (CGON)

Equibles does not estimate personal net worth.

Get an email with a short summary when CG Oncology, Inc. publishes a filing, an earnings call transcript or a press release.

Get CGON alerts

About Jim DeTore

Jim DeTore is recorded as CFO at CG Oncology, Inc. (CGON). The newest filing on record that lists Jim DeTore as CFO at CG Oncology, Inc. (CGON) is dated April 24, 2026. CG Oncology, Inc. reported in an 8-K filed April 13, 2026 that Jim DeTore was appointed Chief Financial Officer, effective April 13, 2026. CG Oncology, Inc. reported in an 8-K filed November 14, 2025 that Jim DeTore was appointed interim principal financial and accounting officer, effective November 17, 2025. The proxy statement of CG Oncology, Inc. reports total compensation of $96,000 for Jim DeTore in fiscal 2025, including a base salary of $96,000. CG Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at CG Oncology, Inc. includes Arthur Kuan (CEO), Corleen M. Roche (CFO), Ambaw Bellete (COO) and 4 others.

“On April 13, 2026, CG Oncology, Inc. (the "Company") appointed Jim DeTore as the Company's Chief Financial Officer.”
CG Oncology, Inc. Form 8-K, filed April 13, 2026 · Read the filing
“On November 14, 2025, the Company appointed Jim DeTore as principal financial and accounting officer of the Company and entered into a Consulting Agreement (the "Consulting Agreement") with Monomoy Advisors, LLC for the provision of such principal financial and accounting officer services by Mr. DeTore.”
CG Oncology, Inc. Form 8-K, filed November 14, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at CG Oncology, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 CG Oncology, Inc. (CGON) $96,000 $96,000

Recent activity